Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam R Johnson

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Bioorganic & Medicinal Chemistry Letters|November 19, 2013
Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORcBenjamin P Fauber, Gladys de Leon Boenig, Brenda Burton, et al.
Journal of Medicinal Chemistry|June 11, 2015
Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonistBenjamin P Fauber, Olivier René, Yuzhong Deng, et al.
Blood|July 19, 2018
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLLSean D Reiff, Elizabeth M Muhowski, Daphne Guinn, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2014
Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonistsBenjamin P Fauber, Olivier René, Gladys de Leon Boenig, et al.
ACS Medicinal Chemistry Letters|March 28, 2015
Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of ActionOlivier René, Benjamin P Fauber, Gladys de Leon Boenig, et al.
Bioorganic & Medicinal Chemistry Letters|June 7, 2015
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonistsBenjamin P Fauber, Alberto Gobbi, Kirk Robarge, et al.
Structure (London, England : 1993)|August 28, 2012
The crystal structure of the catalytic domain of the NF-κB inducing kinase reveals a narrow but flexible active siteGladys de Leon-Boenig, Krista K Bowman, Jianwen A Feng, et al.
ACS Medicinal Chemistry Letters|August 25, 2020
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target ActivityJames J Crawford, Wendy Lee, Adam R Johnson, et al.
The Journal of Biological Chemistry|July 12, 2007
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effectsAdam R Johnson, Alexander G Pavlovsky, Daniel F Ortwine, et al.
ACS Chemical Biology|August 30, 2016
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 MutationsAdam R Johnson, Pawan Bir Kohli, Arna Katewa, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|November 19, 2013
Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORcBenjamin P Fauber, Gladys de Leon Boenig, Brenda Burton, et al.
Journal of Medicinal Chemistry|June 11, 2015
Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonistBenjamin P Fauber, Olivier René, Yuzhong Deng, et al.
Blood|July 19, 2018
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLLSean D Reiff, Elizabeth M Muhowski, Daphne Guinn, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2014
Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonistsBenjamin P Fauber, Olivier René, Gladys de Leon Boenig, et al.
ACS Medicinal Chemistry Letters|March 28, 2015
Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of ActionOlivier René, Benjamin P Fauber, Gladys de Leon Boenig, et al.
Bioorganic & Medicinal Chemistry Letters|June 7, 2015
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonistsBenjamin P Fauber, Alberto Gobbi, Kirk Robarge, et al.
Structure (London, England : 1993)|August 28, 2012
The crystal structure of the catalytic domain of the NF-κB inducing kinase reveals a narrow but flexible active siteGladys de Leon-Boenig, Krista K Bowman, Jianwen A Feng, et al.
ACS Medicinal Chemistry Letters|August 25, 2020
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target ActivityJames J Crawford, Wendy Lee, Adam R Johnson, et al.
The Journal of Biological Chemistry|July 12, 2007
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effectsAdam R Johnson, Alexander G Pavlovsky, Daniel F Ortwine, et al.
ACS Chemical Biology|August 30, 2016
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 MutationsAdam R Johnson, Pawan Bir Kohli, Arna Katewa, et al.
Pageof 6